Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity.
about
Intrathecal baclofen for treating spasticity in children with cerebral palsyThe promise of mHealth: daily activity monitoring and outcome assessments by wearable sensors.Cardiac arrest due to baclofen withdrawal syndrome.The need for and provision of intrathecal baclofen therapy for the management of spasticity in England: an assessment of the Hospital Episode Statistics database.Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore.Elbow spasticity during passive stretch-reflex: clinical evaluation using a wearable sensor system.Evaluation of interadductor approach in neurolytic blockade of obturator nerve in spastic patients.Procedure- and device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review.Intrathecal baclofen in multiple sclerosis: too little, too late?Societal costs of intrathecal drug delivery systems--an administrative analysis based on patient claims.Intrathecal baclofen therapy in children with severe spasticity: Outcome and complications.Spasticity - Pathogenesis, prevention and treatment strategies.Intrathecal baclofen therapy in children with acquired brain injuries after drowning: A case series.Medical cost impact of intrathecal baclofen therapy for severe spasticity.Neuromodulation for spasticity and dystonia.Economic evaluation and cost of interventions for cerebral palsy: a systematic review.Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).Influence of intrathecal baclofen on the level of consciousness and mental functions after extremely severe traumatic brain injury: brief report.
P2860
Q24187762-79CC71C8-0262-4F6E-9F27-79452ECC7415Q33438631-81CA71CB-BE75-47B9-9BCE-7D0F60C9F188Q33629194-6509E0B2-7F4D-493B-BF3C-C22CB5EBADF8Q35803252-7525594F-D433-437D-87F3-D43F9F9CC43AQ36507680-10647353-39CD-49B7-AF79-59BCA81D7E26Q36952387-D039220F-F40B-4808-ADCB-3A49CF4D84CAQ37382010-F3DA5A6D-CE8A-47E3-AFC7-D1A01B40DFC5Q37710249-3C7F0012-546C-41E9-BAA4-01FDD53C65E2Q37833834-301358FC-5E55-4E2E-9379-918E463468E3Q38082835-893D08E9-8BE7-41A7-8B4C-1B069F92B581Q38131529-BFC8464C-DC70-4856-B70D-16059621E913Q38172116-93FCBA32-46D8-4BFA-8756-0ACFEF00F6E8Q38255212-5ABC21D0-1F05-4B27-8D93-6F981D80AD6CQ39141856-87670B1B-BE50-4AFC-B9A8-68C38987598AQ43473646-C825F376-C01F-446C-AD8B-43087BA41371Q47566061-3CFFB140-EC47-4D21-842B-8E317D4864A6Q48125672-F6155723-85C3-4455-AC3F-817350E30CCEQ48442578-BBE0DB07-5F34-4E73-8445-C3B95D5CCFAA
P2860
Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@en
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@nl
type
label
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@en
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@nl
prefLabel
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@en
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness modeling of ...... ions for disabling spasticity.
@en
P2093
A Beresniak
D Bensmail
Leopold Saltuari
P2860
P304
P356
10.1177/1545968308328724
P577
2009-02-19T00:00:00Z